Cosmetics May Provide Analogue for Dysregulation of Drugs

KRISTINE MACKIN | March 27, 2017

article image
I like beauty products – well, it may be more accurate to say that I am interested in beauty products, since most days I only wear a swipe of mascara and concealer to work. However, there are some drawbacks to being interested in beauty; unlike for pharmaceuticals, there are no promises that any product will work.

Spotlight

Fertin Pharma A/S

At Fertin Pharma we specialize in developing and producing medicated chewing gum. As one of the world’s leading providers of nicotine chewing gum, we aid smokers all around the world in their effort to stop smoking. Our mission – Supporting healthy living – is carried out through our continuous desire to create the best medicated chewing gum products in the market.

OTHER ARTICLES

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | April 1, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | April 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | April 1, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Spotlight

Fertin Pharma A/S

At Fertin Pharma we specialize in developing and producing medicated chewing gum. As one of the world’s leading providers of nicotine chewing gum, we aid smokers all around the world in their effort to stop smoking. Our mission – Supporting healthy living – is carried out through our continuous desire to create the best medicated chewing gum products in the market.

Events